Meeting
2017 ASCO Annual Meeting
Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).
Authors
Salomon M. Stemmer
Davidoff Cancer Center, Tel Aviv, Israel
Salomon M. Stemmer , Mariana Steiner , Shulamith Rizel , Noa Ben Baruch , Lior Soussan-Gutman , Avital Bareket-Samish , Bella Nisenbaum , Kevin Isaacs , Georgeta Fried , Ora Rosengarten , Tamar Peretz , Christer Svedman , Debbie McCullough , Shmuel Klang , Jamal Zidan , Larisa Ryvo , Bella Kaufman , Steven Shak , Nicky Liebermann , David B Geffen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 543)
DOI
10.1200/JCO.2017.35.15_suppl.543
Abstract #
543
Poster Bd #
143
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).
First Author: Adam Brufsky
Poster
2015 Breast Cancer Symposium
Distant recurrence risk with prospective use of the 21-gene assay at a single institution.
First Author: John Mullinax
First Author: Christy Ann Russell
Poster
2013 Breast Cancer Symposium
21-gene recurrence score testing and subsequent treatment decisions in patients (pts) with estrogen-receptor–positive (ER+) early-stage breast cancer (ESBC).
First Author: Jennifer B. Manders